Onconova Therapeutic (ONTX) 6.28 $ONTX
Onconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine Combination at 2016 ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 4:00PM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data relating to the mechanistic rationale for combining rigosertib with azacitidine at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7 in Chicago, Illinois.
ONTX: 6.28 (-0.59)
Onconova Files S-1 Registration Statement for Rights Offering to Shareholders
GlobeNewswire - Wed Jun 01, 5:30PM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova" or the "Company"
, a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced it filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC" for a rights offering to its existing stockholders.
ONTX: 6.28 (-0.59)
Onconova Announces Upcoming Presentations Related to Advanced Rigosertib Clinical Trials at 2016 ASCO Annual Meeting
GlobeNewswire - Tue May 31, 7:45AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced details relating to two poster presentations at the upcoming 2016 American Society of Clinical Oncology Annual Meeting taking place June 3-7 in Chicago, Illinois.
ONTX: 6.28 (-0.59)
Onconova Therapeutics, Inc. Announces Appointment of Jack E. Stover to Board of Directors
GlobeNewswire - Mon May 23, 7:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Jack E. Stover has been appointed to its Board of Directors.
ONTX: 6.28 (-0.59), IDXG: 0.34 (+0.02), PDII: 0.53 (-0.02)
Onconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten Reverse Stock Split
GlobeNewswire - Fri May 20, 7:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced results from its 2016 annual meeting of stockholders. At the annual meeting, Onconova stockholders voted to approve a reverse stock split of the company's common stock by a ratio of not less than one-for-eight and not more than one-for-twelve. The company's board of directors subsequently fixed the reverse stock split ratio at one-for-ten and fixed the record date for the reverse stock split.
ONTX: 6.28 (-0.59)
Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 3:05PM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.
ONTX: 6.28 (-0.59)
Onconova Announces Publication Describing Unique RAS-targeted Mechanism of Action for Rigosertib in the Journal Cell
GlobeNewswire - Thu Apr 21, 6:00PM CDT
-- More than 30% of all human cancers driven by RAS, a target previously considered "undruggable"--
ONTX: 6.28 (-0.59)
Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in Presentation at 2016 American Association of Cancer Research (AACR) Annual Meeting
GlobeNewswire - Wed Apr 20, 7:30AM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of pre-clinical data for its first-in-class dual inhibitor of ARK5 and CDK4/6 at the 2016 AACR Annual Meeting being held April 16-20, 2016 at the Ernest N. Morial Convention Center in New Orleans, LA.
ONTX: 6.28 (-0.59)
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2015 Financial Results
GlobeNewswire - Mon Mar 28, 7:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the fourth quarter and year-ended December 31, 2015.
ONTX: 6.28 (-0.59)
Onconova Starts Phase III INSPIRE Study on Rigosertib in EU
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 8:30AM CDT
Onconova (ONTX) initiates patient enrolment in the phase III INSPIRE study on IV rigosertib in the EU.
SHPG: 177.10 (-6.85), ONTX: 6.28 (-0.59), BXLT: 46.02 (-0.18), CELG: 102.91 (-3.22)
Onconova Enrolls First Patient in Europe for Phase 3 INSPIRE Trial of Rigosertib in Higher-Risk Myelodysplastic Syndromes
GlobeNewswire - Mon Mar 21, 6:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the enrollment of the first European patient in Salzburg, Austria for the Phase 3 INSPIRE trial for IV rigosertib as a treatment for higher-risk myelodysplastic syndromes (HR-MDS) following failure of hypomethylating agent (HMA) therapy. The first patient in this global trial was enrolled at the MD Anderson Cancer Center in December 2015.
ONTX: 6.28 (-0.59)
Onconova Announces Publication of Rigosertib Phase 3 ONTIME Data in Lancet Oncology
GlobeNewswire - Wed Mar 09, 6:01AM CST
-- Online-First Publication Currently Available --
ONTX: 6.28 (-0.59)
Onconova Therapeutics, Inc. Receives Notice of Termination for Convenience from Baxalta
GlobeNewswire - Thu Mar 03, 6:10PM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, received notice today from Baxalta US Inc. of Baxalta's termination of the September 2012 development and license agreement between Baxalta and Onconova for rigosertib, Onconova's lead development candidate. Onconova, following prior consultation with Baxalta, began enrolling the first of approximately 225 patients in December 2015 for the INSPIRE trial for IV rigosertib as a treatment for higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agent (HMA) therapy.
ONTX: 6.28 (-0.59)
Onconova Therapeutics, Inc. Announces Listing Transfer to NASDAQ Capital Market
GlobeNewswire - Thu Feb 04, 4:01PM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it received a positive determination from the NASDAQ Stock Market granting approval of the Company's request to transfer its listing to the NASDAQ Capital Market from the NASDAQ Global Select Market. The Company's securities will begin trading on the NASDAQ Capital Market effective at the start of trading on Friday, February 5, 2016. The Company's shares will continue to trade on NASDAQ under the symbol "ONTX."
ONTX: 6.28 (-0.59)
Essential Thrombocythemia Therapeutics Development Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/n57crm/essential) has announced the addition of the "Essential Thrombocythemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Essential Thrombocythemia Overview - Therapeutics Development - Pipeline Products for Essential Thrombocythemia - Overview - Pipeline Products for Essential Thrombocythemia - Comparative Analysis - Essential Thrombocythemia - Therapeutics under Development by Companies - Essential Thrombocythemia - Therapeutics under Investigation by Universities/Institutes - Essential Thrombocythemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Essential Thrombocythemia - Products under Development by Companies - Essential Thrombocythemia - Products under Investigation by Universities/Institutes - Essential Thrombocythemia - Companies Involved in Therapeutics Development - Aop Orphan Pharmaceuticals AG - Galena Biopharma, Inc. - Incyte Corporation - Italfarmaco S.p.A. - Novartis AG - Onconova Therapeutics, Inc. - PharmaEssentia Corporation For more information visit http://www.researchandmarkets.com/research/n57crm/essential
INCY: 80.41 (-1.20), ONTX: 6.28 (-0.59), GALE: 2.08 (+0.10), NVS: 78.94 (-1.57)
Onconova Therapeutics, Inc. to Present Corporate Update at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 01, 7:02AM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and Chief Executive Officer, will present a company update at the 18 Annual BIO CEO & Investor Conference in New York, NY. The presentation will take place on Monday, February 8 at 4:00 p.m. ET.
ONTX: 6.28 (-0.59)
Onconova Therapeutics Announces Registered Direct Offering
GlobeNewswire - Wed Jan 06, 7:45AM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it has entered into a definitive agreement with a single institutional investor to receive gross proceeds of approximately $1.84 million.
ONTX: 6.28 (-0.59)
Refractory Anemia With Ringed Sideroblasts Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/4qgqf3/refractory_anemia) has announced the addition of the "Refractory Anemia With Ringed Sideroblasts Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Refractory Anemia With Ringed Sideroblasts Global Clinical Trials Review, H2, 2015" provides an overview of Refractory Anemia With Ringed Sideroblasts clinical trials scenario. This report provides top line data relating to the clinical trials on Refractory Anemia With Ringed Sideroblasts. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Actinium Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - SymBio Pharmaceuticals Limited - Onconova Therapeutics, Inc. - Johnson & Johnson - Jaguar Holding Company II - F. Hoffmann-La Roche Ltd. For more information visit http://www.researchandmarkets.com/research/4q...ory_anemia
JNJ: 117.01 (+0.01), ATNM: 1.82 (unch), SNDX: 13.17 (-0.41), ONTX: 6.28 (-0.59)
Onconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine Combination at 2016 ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 4:00PM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data relating to the mechanistic rationale for combining rigosertib with azacitidine at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7 in Chicago, Illinois.
ONTX: 6.28 (-0.59)
Onconova Files S-1 Registration Statement for Rights Offering to Shareholders
GlobeNewswire - Wed Jun 01, 5:30PM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova" or the "Company"
, a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced it filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC" for a rights offering to its existing stockholders. ONTX: 6.28 (-0.59)
Onconova Announces Upcoming Presentations Related to Advanced Rigosertib Clinical Trials at 2016 ASCO Annual Meeting
GlobeNewswire - Tue May 31, 7:45AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced details relating to two poster presentations at the upcoming 2016 American Society of Clinical Oncology Annual Meeting taking place June 3-7 in Chicago, Illinois.
ONTX: 6.28 (-0.59)
Onconova Therapeutics, Inc. Announces Appointment of Jack E. Stover to Board of Directors
GlobeNewswire - Mon May 23, 7:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Jack E. Stover has been appointed to its Board of Directors.
ONTX: 6.28 (-0.59), IDXG: 0.34 (+0.02), PDII: 0.53 (-0.02)
Onconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten Reverse Stock Split
GlobeNewswire - Fri May 20, 7:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced results from its 2016 annual meeting of stockholders. At the annual meeting, Onconova stockholders voted to approve a reverse stock split of the company's common stock by a ratio of not less than one-for-eight and not more than one-for-twelve. The company's board of directors subsequently fixed the reverse stock split ratio at one-for-ten and fixed the record date for the reverse stock split.
ONTX: 6.28 (-0.59)
Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 3:05PM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.
ONTX: 6.28 (-0.59)
Onconova Announces Publication Describing Unique RAS-targeted Mechanism of Action for Rigosertib in the Journal Cell
GlobeNewswire - Thu Apr 21, 6:00PM CDT
-- More than 30% of all human cancers driven by RAS, a target previously considered "undruggable"--
ONTX: 6.28 (-0.59)
Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in Presentation at 2016 American Association of Cancer Research (AACR) Annual Meeting
GlobeNewswire - Wed Apr 20, 7:30AM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of pre-clinical data for its first-in-class dual inhibitor of ARK5 and CDK4/6 at the 2016 AACR Annual Meeting being held April 16-20, 2016 at the Ernest N. Morial Convention Center in New Orleans, LA.
ONTX: 6.28 (-0.59)
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2015 Financial Results
GlobeNewswire - Mon Mar 28, 7:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the fourth quarter and year-ended December 31, 2015.
ONTX: 6.28 (-0.59)
Onconova Starts Phase III INSPIRE Study on Rigosertib in EU
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 8:30AM CDT
Onconova (ONTX) initiates patient enrolment in the phase III INSPIRE study on IV rigosertib in the EU.
SHPG: 177.10 (-6.85), ONTX: 6.28 (-0.59), BXLT: 46.02 (-0.18), CELG: 102.91 (-3.22)
Onconova Enrolls First Patient in Europe for Phase 3 INSPIRE Trial of Rigosertib in Higher-Risk Myelodysplastic Syndromes
GlobeNewswire - Mon Mar 21, 6:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the enrollment of the first European patient in Salzburg, Austria for the Phase 3 INSPIRE trial for IV rigosertib as a treatment for higher-risk myelodysplastic syndromes (HR-MDS) following failure of hypomethylating agent (HMA) therapy. The first patient in this global trial was enrolled at the MD Anderson Cancer Center in December 2015.
ONTX: 6.28 (-0.59)
Onconova Announces Publication of Rigosertib Phase 3 ONTIME Data in Lancet Oncology
GlobeNewswire - Wed Mar 09, 6:01AM CST
-- Online-First Publication Currently Available --
ONTX: 6.28 (-0.59)
Onconova Therapeutics, Inc. Receives Notice of Termination for Convenience from Baxalta
GlobeNewswire - Thu Mar 03, 6:10PM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, received notice today from Baxalta US Inc. of Baxalta's termination of the September 2012 development and license agreement between Baxalta and Onconova for rigosertib, Onconova's lead development candidate. Onconova, following prior consultation with Baxalta, began enrolling the first of approximately 225 patients in December 2015 for the INSPIRE trial for IV rigosertib as a treatment for higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agent (HMA) therapy.
ONTX: 6.28 (-0.59)
Onconova Therapeutics, Inc. Announces Listing Transfer to NASDAQ Capital Market
GlobeNewswire - Thu Feb 04, 4:01PM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it received a positive determination from the NASDAQ Stock Market granting approval of the Company's request to transfer its listing to the NASDAQ Capital Market from the NASDAQ Global Select Market. The Company's securities will begin trading on the NASDAQ Capital Market effective at the start of trading on Friday, February 5, 2016. The Company's shares will continue to trade on NASDAQ under the symbol "ONTX."
ONTX: 6.28 (-0.59)
Essential Thrombocythemia Therapeutics Development Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/n57crm/essential) has announced the addition of the "Essential Thrombocythemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Essential Thrombocythemia Overview - Therapeutics Development - Pipeline Products for Essential Thrombocythemia - Overview - Pipeline Products for Essential Thrombocythemia - Comparative Analysis - Essential Thrombocythemia - Therapeutics under Development by Companies - Essential Thrombocythemia - Therapeutics under Investigation by Universities/Institutes - Essential Thrombocythemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Essential Thrombocythemia - Products under Development by Companies - Essential Thrombocythemia - Products under Investigation by Universities/Institutes - Essential Thrombocythemia - Companies Involved in Therapeutics Development - Aop Orphan Pharmaceuticals AG - Galena Biopharma, Inc. - Incyte Corporation - Italfarmaco S.p.A. - Novartis AG - Onconova Therapeutics, Inc. - PharmaEssentia Corporation For more information visit http://www.researchandmarkets.com/research/n57crm/essential
INCY: 80.41 (-1.20), ONTX: 6.28 (-0.59), GALE: 2.08 (+0.10), NVS: 78.94 (-1.57)
Onconova Therapeutics, Inc. to Present Corporate Update at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 01, 7:02AM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and Chief Executive Officer, will present a company update at the 18 Annual BIO CEO & Investor Conference in New York, NY. The presentation will take place on Monday, February 8 at 4:00 p.m. ET.
ONTX: 6.28 (-0.59)
Onconova Therapeutics Announces Registered Direct Offering
GlobeNewswire - Wed Jan 06, 7:45AM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it has entered into a definitive agreement with a single institutional investor to receive gross proceeds of approximately $1.84 million.
ONTX: 6.28 (-0.59)
Refractory Anemia With Ringed Sideroblasts Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/4qgqf3/refractory_anemia) has announced the addition of the "Refractory Anemia With Ringed Sideroblasts Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Refractory Anemia With Ringed Sideroblasts Global Clinical Trials Review, H2, 2015" provides an overview of Refractory Anemia With Ringed Sideroblasts clinical trials scenario. This report provides top line data relating to the clinical trials on Refractory Anemia With Ringed Sideroblasts. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Actinium Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - SymBio Pharmaceuticals Limited - Onconova Therapeutics, Inc. - Johnson & Johnson - Jaguar Holding Company II - F. Hoffmann-La Roche Ltd. For more information visit http://www.researchandmarkets.com/research/4q...ory_anemia
JNJ: 117.01 (+0.01), ATNM: 1.82 (unch), SNDX: 13.17 (-0.41), ONTX: 6.28 (-0.59)
